Clinical trial milestone alerts by email

Why this feed exists

The earliest reliable signal in a drug program is not the press release — it is the registry. A new Phase 3, a trial advancing a stage, a primary-completion date arriving, results first posted: these land on ClinicalTrials.gov weeks to months before the announcement, and often with no announcement at all. This feed watches industry-sponsored Phase 2 and Phase 3 trials across every condition, so a program's momentum is visible while it is still building.

What each alert includes

An AI headline naming the sponsor, the trial phase, and what changed, the record's key facts pulled straight from the registry, and a Market read on the trajectory: which listed company the trial belongs to, how far along it is, and whether the change points toward a near-term catalyst.

What we filter, honestly

The registry logs a great deal of routine housekeeping. This feed reads each change for what it implies about a program's direction and scores cosmetic amendments low, so the advances that actually move a timeline stand out. A registry change is a leading signal, not a same-day event — it is the heads-up, not the headline.

What it costs

Your first feed is free.